Last reviewed · How we verify
Taigexyn (NEMONOXACIN)
Taigexyn (generic name: NEMONOXACIN) is a drug. It is currently in Phase 3 development for Community acquired pneumonia.
Taigexyn works by inhibiting bacterial DNA replication and transcription.
Taigexyn, also known as Nemonoxacin, is a small molecule that inhibits bacterial DNA gyrase, a mechanism that targets bacterial DNA replication. It has been studied for its safety and efficacy in treating Diabetic Foot Infections and Pneumonia, with doses of 500 mg and 650 mg being investigated.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NEMONOXACIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Think of it like a copy machine. Bacteria make copies of their DNA to multiply. Taigexyn blocks this process, preventing the bacteria from making more copies and eventually killing them.
Approved indications
- Community acquired pneumonia
Common side effects
Key clinical trials
- Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections (PHASE2)
- Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride (PHASE2)
- Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study
- Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia (PHASE3)
- Oral Nemonoxacin in Treating Elderly Patients With CAP (PHASE4)
- A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP (PHASE3)
- Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function (PHASE1)
- Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taigexyn CI brief — competitive landscape report
- Taigexyn updates RSS · CI watch RSS
Frequently asked questions about Taigexyn
What is Taigexyn?
How does Taigexyn work?
What is Taigexyn used for?
What is the generic name of Taigexyn?
What development phase is Taigexyn in?
Related
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Community acquired pneumonia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing